SCHEMBL4238927

SCHEMBL4238927

CCc1cc(NC(=O)NC(CC)CC)ccc1Oc1ccc(N)cc1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PKM P14618 2/20 0.54
▸ TAS1R3 Q7RTX0 1/20 0.46
▸ TAS1R1 Q7RTX1 1/20 0.46
▸ CYP2C9 P11712 1/20 0.41
▸ CYP2C19 P33261 1/20 0.41
▸ MAPK14 Q16539 1/20 0.41
▸ ALDH1A1 P00352 1/20 0.41
▸ RAB9A P51151 2/20 0.38
▸ NPC1 O15118 1/20 0.38
▸ TP53 P04637 1/20 0.38
▸ SMN1; SMN2 Q16637 1/20 0.38
▸ PNLIP P16233 1/20 0.38
▸ MAPT P10636 2/20 0.38
▸ MAPK1 P28482 1/20 0.37
▸ TDP1 Q9NUW8 1/20 0.36
▸ MTNR1B P49286 1/20 0.36
▸ NPY5R Q15761 1/20 0.36
▸ KDM4E B2RXH2 1/20 0.35
▸ MEN1 O00255 1/20 0.35
▸ LMNA P02545 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4236335 0.91 PKM (0.53) PKMTAS1R3TAS1R1CYP2C9CYP2C19
SCHEMBL4228260 0.88 PKM (0.54) PKMTAS1R3TAS1R1CYP2C9CYP2C19
SCHEMBL4229305 0.87 PKM (0.60) PKMTAS1R3TAS1R1ALDH1A1RAB9A
SCHEMBL4236991 0.87 PKM (0.53) PKMTAS1R3TAS1R1CYP2C9CYP2C19
SCHEMBL4240850 0.87 PKM (0.53) PKMTAS1R3TAS1R1PNLIPMAPT
SCHEMBL4228811 0.87 PKM (0.60) PKMTAS1R3TAS1R1ALDH1A1RAB9A
SCHEMBL5149411 0.86 PKM (0.52) PKMTAS1R3TAS1R1CYP2C9CYP2C19
SCHEMBL4236665 0.86 PKM (0.52) PKMTAS1R3TAS1R1CYP2C9CYP2C19
Ammonia Solution, Strong SCHEMBL4235457 0.86 PKM (0.58) PKMTAS1R3TAS1R1ALDH1A1RAB9A
SCHEMBL4238162 0.86 PKM (0.52) PKMTAS1R3TAS1R1CYP2C9CYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090233910-A1 Npy antagonists, preparation and uses CEREP (FR) 2009-09-17 — — US disclosed
US-20090233910-A1 Npy antagonists, preparation and uses CEREP (FR) 2009-09-17 — — US disclosed
US-20090233910-A1 Npy antagonists, preparation and uses CEREP (FR) 2009-09-17 — — US disclosed
EP-1879887-A2 NPY ANTAGONISTS, PREPARATION AND USE Cerep (FR) 2008-01-23 — — EP disclosed
WO-2006108965-A2 NPY ANTAGONISTS, PREPARATION AND USE CEREP (FR) 2006-10-19 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090233910-A1 Npy antagonists, preparation and uses NPY1R, NPY5R, NPY2R PKM 1734/4885TAS1R3 1436/4885TAS1R1 1073/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback